Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
GHK-Cu (Scalp) vs Matrixyl (Palmitoyl Pentapeptide-4)
An educational, source-based comparison of GHK-Cu (Scalp) and Matrixyl (Palmitoyl Pentapeptide-4) — how each peptide works, what it's researched for, and what to know before going deeper.
Topical GHK-Cu applied to the scalp has been studied for its ability to enlarge hair follicles, prolong the anagen growth phase, and improve perifollicular vascularization through copper-dependent gene modulation.
- Follicle size and anagen phase
- Perifollicular angiogenesis
- Post-procedure scalp recovery (microneedling, transplant)
- • Topical use has a long cosmetic safety record.
- • Not a replacement for evidence-based therapies like minoxidil or finasteride.
Topical matrikine researched for collagen stimulation.
A signal peptide that mimics the procollagen-I fragment, stimulating fibroblasts to produce collagen, elastin, and glycosaminoglycans in topical cosmetic research.
- Dermal collagen synthesis
- Fine lines and skin firmness
- • Well tolerated in topical use.
- • Modest improvements; not equivalent to retinoids.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| GHK-Cu (Scalp) | Copper peptides and hair growth | Journal of the American Academy of Dermatology | 2007 | Reported follicular stimulation and improved hair density in early trials. |
| Matrixyl (Palmitoyl Pentapeptide-4) | Palmitoyl pentapeptide-4 in anti-aging skincare | International Journal of Cosmetic Science | 2005 | Improved wrinkle parameters versus placebo in topical trial. |
Side-effect & safety grid
- Topical use has a long cosmetic safety record.
- Not a replacement for evidence-based therapies like minoxidil or finasteride.
- Well tolerated in topical use.
- Modest improvements; not equivalent to retinoids.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
GHK-Cu (Scalp) vs Matrixyl (Palmitoyl Pentapeptide-4) — Key differences
- Class: GHK-Cu (Scalp) is classified as Hair · Follicle Health, while Matrixyl (Palmitoyl Pentapeptide-4) is Skin · Collagen.
- Primary research focus: GHK-Cu (Scalp) — follicle size and anagen phase; Matrixyl (Palmitoyl Pentapeptide-4) — dermal collagen synthesis.
- Tag: Hair vs Skin.
GHK-Cu (Scalp) Research Protocol Table
Structured summary of dosing, routes, and durations as described in published research and FDA labels. Educational reference only — not dosing guidance.
| Context | Population | Route | Dose | Duration | Notes |
|---|---|---|---|---|---|
| Follicle-size and hair-growth research (scalp application) | Rodent models and small human scalp studies | Topical solution or serum applied to scalp | Formulations commonly studied in the ~0.05–0.2% copper-tripeptide range | 8–24 weeks in published protocols | Copper-peptide scalp studies report changes in follicle size and hair density; sample sizes are small and formulations are not standardised across studies. |
| Perifollicular tissue remodeling | In vitro dermal papilla and fibroblast cultures | Culture medium | Nanomolar to low-micromolar concentrations | 24–72 hours | Cell-culture work associates GHK-Cu with increased collagen and decorin expression and modulation of TGF-beta signaling — mechanistic context, not a hair-growth claim. |
| Post-procedure scalp recovery research | Adults following microneedling or transplant procedures (small clinical series) | Topical, applied after the procedure per study protocol | Study-specific serum concentrations | 4–12 weeks | Explored for wound-environment support rather than as a hair-loss therapy; evidence is preliminary. |
GHK-Cu (Scalp) — Frequently Asked Questions
Is GHK-Cu researched for hair growth?+
GHK-Cu appears in a small body of research on scalp and follicle biology, where copper peptides are associated with increased follicle size and changes in the perifollicular matrix in animal models and small human studies. It is not an FDA-approved hair-loss treatment, and the evidence base is far smaller than that for minoxidil or finasteride.
How is GHK-Cu thought to affect hair follicles?+
The proposed mechanism is indirect: GHK-Cu is studied for stimulating collagen, decorin and glycosaminoglycan production, improving the dermal environment surrounding the follicle, and modulating TGF-beta signaling. Better perifollicular matrix quality is the hypothesised route to larger follicles, rather than direct hormonal action on the hair cycle.
Is GHK-Cu applied topically or injected in hair research?+
Hair-related research overwhelmingly uses topical scalp application, typically as a serum or solution, sometimes paired with microneedling in small clinical series. Injectable use for hair purposes is not supported by published controlled evidence.
How does GHK-Cu compare with minoxidil?+
They are not comparable in evidence weight. Minoxidil is FDA-approved for androgenetic alopecia with decades of controlled trial data; GHK-Cu is a research-stage cosmetic peptide with small studies and no approval for hair loss. They are sometimes discussed as complementary in cosmetic formulation research, but no controlled trial establishes a combined benefit.
How long do studies run before measuring hair outcomes?+
Hair-cycle research generally requires at least 12–24 weeks before density or diameter changes are measurable, because anagen re-entry is slow. Shorter studies mostly report on scalp condition and tolerability rather than growth endpoints.
Is topical GHK-Cu considered well tolerated?+
Cosmetic-formulation studies generally report good local tolerability, with occasional irritation or contact sensitivity. Copper-peptide products vary widely in concentration and vehicle, and none is standardised or regulated as a drug — a patch test and clinician input remain sensible.